AGenome-Wide Association Study ofMyasthenia Gravis
暂无分享,去创建一个
Sonja W. Scholz | Hannah A. Pliner | Janel O. Johnson | D. Hernandez | M. Nalls | A. Pestronk | A. Chiò | B. Traynor | M. Benatar | D. Richman | A. Soloway | S. Arepalli | J. R. Gibbs | M. Pasnoor | A. Renton | R. Barohn | J. Kissel | J. Howard | D. Sanders | Z. Siddiqi | M. Maestri | G. Restagno | M. Freimer | A. Mcvey | M. Dimachkie | M. Mezei | H. Kaminski | J. Massey | D. Drachman | A. Corse | M. Nicolle | M. Chopra | W. Koopman | R. Pascuzzi | A. Evoli | M. Macek | J. Rowin | V. Chaudhry | F. Scuderi | C. Provenzano | E. Bartoccioni | J. Florence | D. Blackmore | E. Errichiello | R. Ricciardi | T. Jiwa | Bernadette Lipscomb | C. Wulf | Yevgeniya A. Abramzon
[1] M. Nalls,et al. Genome-wide analysis of the heritability of amyotrophic lateral sclerosis. , 2014, JAMA neurology.
[2] R. Lewis,et al. Autoantibodies to Agrin in Myasthenia Gravis Patients , 2014, PloS one.
[3] Mohamad Saad,et al. Using genome-wide complex trait analysis to quantify 'missing heritability' in Parkinson's disease. , 2013, Human molecular genetics.
[4] Soumya Raychaudhuri,et al. Risk for myasthenia gravis maps to a 151Pro→Ala change in TNIP1 and to human leukocyte antigen‐B*08 , 2012, Annals of neurology.
[5] R. Mantegazza,et al. Autoimmune mechanisms in myasthenia gravis. , 2012, Current opinion in neurology.
[6] L. Liang,et al. A genome-wide association study identifies two new risk loci for Graves' disease , 2011, Nature Genetics.
[7] G. Anderson,et al. Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4 , 2011, Science.
[8] P. Visscher,et al. Estimating missing heritability for disease from genome-wide association studies. , 2011, American journal of human genetics.
[9] Y. Yamanashi,et al. Autoantibodies to low‐density lipoprotein receptor–related protein 4 in myasthenia gravis , 2011, Annals of neurology.
[10] A. Sanchez‐Mazas,et al. HLA DNA Sequence Variation among Human Populations: Molecular Signatures of Demographic and Selective Events , 2011, PloS one.
[11] V. Krishnamurthi. A Phase III Study of Belatacept-based Immunosuppression Regimens versus Cyclosporine in Renal Transplant Recipients (BENEFIT Study) , 2010 .
[12] J. Nutt,et al. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson’s disease , 2010, Nature Genetics.
[13] P. Visscher,et al. Common SNPs explain a large proportion of the heritability for human height , 2010, Nature Genetics.
[14] C. Cardwell,et al. A systematic review of population based epidemiological studies in Myasthenia Gravis , 2010, BMC neurology.
[15] P. Deloukas,et al. Multiple common variants for celiac disease influencing immune gene expression , 2010, Nature Genetics.
[16] Larry W. Moreland,et al. REL, a member of the NF-κB family of transcription factors, is a newly defined risk locus for rheumatoid arthritis , 2009, Nature Genetics.
[17] D. Clayton,et al. Genome-wide association study and meta-analysis finds over 40 loci affect risk of type 1 diabetes , 2009, Nature Genetics.
[18] A. Alshekhlee,et al. Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals , 2009, Neurology.
[19] David Mellis,et al. Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations. , 2008, American journal of human genetics.
[20] J. Aarli. Myasthenia Gravis in the Elderly , 2008, Annals of the New York Academy of Sciences.
[21] M. Daly,et al. Estimation of the multiple testing burden for genomewide association studies of nearly all common variants , 2008, Genetic epidemiology.
[22] R. Pirskanen,et al. Two SNPs in the promoter region of the CTLA‐4 gene affect binding of transcription factors and are associated with human myasthenia gravis , 2007, Journal of internal medicine.
[23] M. Dougados,et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate , 2007, Annals of the rheumatic diseases.
[24] K. Chan,et al. Frequency of seronegativity in adult‐acquired generalized myasthenia gravis , 2007, Muscle & nerve.
[25] R. Lisak,et al. Myasthenic crisis: Guidelines for prevention and treatment , 2007, Journal of the Neurological Sciences.
[26] Manuel A. R. Ferreira,et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.
[27] Paul Garside,et al. Reversal of the TCR Stop Signal by CTLA-4 , 2006, Science.
[28] S. Gabriel,et al. Assessing the impact of population stratification on genetic association studies , 2004, Nature Genetics.
[29] P. Tonali,et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. , 2003, Brain : a journal of neurology.
[30] A. Vincent,et al. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies , 2001, Nature Medicine.
[31] J. Mendell,et al. Myasthenia Gravis and Associated Autoimmune Diseases in Children , 2000, Journal of child neurology.
[32] E. Stålberg,et al. SFEMG in ocular myasthenia gravis diagnosis , 2000, Clinical Neurophysiology.
[33] W. Dougall,et al. RANK is essential for osteoclast and lymph node development. , 1999, Genes & development.
[34] P. Linsley,et al. Immunotherapy of experimental autoimmune myasthenia gravis: selective effects of CTLA4Ig and synergistic combination with an IL2-Diphtheria toxin fusion protein , 1998, Journal of Neuroimmunology.
[35] P. Szabo,et al. Effect of age on humoral immunity, selection of the B‐cell repertoire and B‐cell development , 1997, Immunological reviews.
[36] R. Dubose,et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function , 1997, Nature.
[37] H. Garchon,et al. Association of the AChRalpha-subunit gene (CHRNA), DQA1*0101, and the DR3 haplotype in myasthenia gravis. Evidence for a three-gene disease model in a subgroup of patients. , 1997, Journal of autoimmunity.
[38] H. Griesser,et al. Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4 , 1995, Science.
[39] P. Linsley,et al. Immunosuppression and induction of anergy by CTLA4Ig in vitro: effects on cellular and antibody responses of lymphocytes from rats with experimental autoimmune myasthenia gravis. , 1995, Cellular immunology.
[40] I. Tsiropoulos,et al. Associated autoimmune diseases in myasthenia gravis A population‐based study , 1995, Acta neurologica Scandinavica.
[41] J. Weber,et al. Genetic linkage of familial expansile osteolysis to chromosome 18q. , 1994, Human molecular genetics.
[42] R. Lovelace,et al. Seronegative myasthenia gravis , 1988, Neurology.
[43] R. Pirskanen. GENETIC ASPECTS IN MYASTHENIA GRAVIS , 1977, Acta neurologica Scandinavica.
[44] D. Elmqvist. Myasthenia Gravis , 1975, The Lancet.
[45] D. Grob,et al. Familial myasthenia gravis. Report of 27 patients in 12 families and review of 164 patients in 73 families. , 1971, Archives of neurology.
[46] Simon C. Potter,et al. Using genome-wide complex trait analysis to quantify ‘ missing heritability ’ in Parkinson ’ s disease , 2012 .
[47] W. G. Hill,et al. Genome partitioning of genetic variation for complex traits using common SNPs , 2011, Nature Genetics.
[48] Peter Dalgaard,et al. R Development Core Team (2010): R: A language and environment for statistical computing , 2010 .
[49] G. Abecasis,et al. Genotype imputation. , 2009, Annual review of genomics and human genetics.
[50] R. Pirskanen,et al. Different HLA DR-DQ associations in subgroups of idiopathic myasthenia gravis , 2005, Immunogenetics.
[51] A. Szobor. Myasthenia gravis: familial occurrence. A study of 1100 myasthenia gravis patients. , 1989, Acta medica Hungarica.